Benefits of MRD Testing for the Treatment of Patients With Multiple Myeloma

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, argued in favor of minimal residual disease (MRD) testing for patients with multiple myeloma, in both a research setting and in clinical practice.


Make an Appointment

Related Articles